AstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients

LONDON (Reuters) – AstraZeneca (NASDAQ:AZN)’s lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of...